undamentalytics Newsletter
Sign in

Moderna balance sheet

At the end of fiscal 2025, Moderna had total assets of $12.34bn, total liabilities of $3.69bn and shareholders' equity of $8.65bn. It held $2.60bn in cash against $590m of debt: net cash of $2.00bn.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents0.10.10.70.22.66.83.22.91.92.61.7
Receivables—0.00.00.01.43.21.40.90.40.20.0
Inventory———0.00.01.40.90.20.10.20.3
Total current assets—0.81.61.16.316.113.410.38.16.55.8
Goodwill——————0.00.10.10.10.1
Total assets—1.12.01.67.324.725.918.414.112.311.0
Accounts payable—0.00.00.00.00.30.50.50.40.30.2
Deferred revenue (current)—0.10.10.13.96.32.00.60.20.10.3
Total current liabilities—0.20.20.14.49.14.93.02.22.02.5
Long-term debt————————0.00.60.6
Total debt0.00.0—0.00.00.00.00.00.00.60.6
Total liabilities—0.50.40.44.810.56.74.63.23.74.2
Shareholders' equity−0.3−0.61.51.22.614.119.113.910.98.76.8
Non-controlling interests and other (assets − liabilities − equity)—1.20.1————————
Net debt (negative = net cash)−0.1−0.1−0.7−0.2−2.6−6.8−3.2−2.9−1.9−2.0−1.1
Shares outstanding—261m329m337m399m403m385m382m386m394m399m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: EXEL vs MRNAMRNA vs NTRAALKS vs MRNA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Moderna's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Moderna.